Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAZETTA trial of tazemetostat in unresectable or metastatic epithelioid sarcoma
jRCT2031220523Phase 2Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tazemetostat in epithelioid sarcoma (ES), sponsored by Eisai Co., Ltd. Primary endpoint: Progression-free survival rate at 18 weeks. Started Dec 2022; status: active, not recruiting.
02
Drugs
tazemetostat
03
Conditions
epithelioid sarcoma (ES)
Beyond the preview
Go deeper on jRCT2031220523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220523.